Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

• Status: Recruiting
• Trial end date: 2024-08-30
• Target enrollment: 0
• Participant gender: All

Summary

In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Netherlands Cancer Institute
• Collaborator: Hoffmann-La Roche
• Treatments: Antibodies, Monoclonal; Atezolizumab; Bevacizumab

Criteria

Inclusion Criteria:

• signed informed consent

• patients age 18 years and older

• histologically confirmed adenocarcinoma of the rectum

• intermediate risk rectal cancer or low risk distal rectal cancer

Exclusion Criteria:

• evidence of metastatic disease

• prior radiation therapy for disease under study

• prior treatment with CD137 agonists or immune checkpoint blockade therapies

• current or recent use of acetylsalicylic acid

• history of clinically significant cardiac or pulmonary dysfunction pregnancy or breastfeeding

• significant auto-immune disease